Sign in Create account

Aarey Drugs & Pharmaceuticals Limited

Healthcare · Pharmaceuticals & Biotechnology

NSE: AAREYDRUGS BSE: 524412
₹102.72
▲ 2.80 (2.80%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
42/100
Moderate
Valuation
41/100
Fairly Valued
Momentum
55/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Fairly Valued, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹291 Cr
PE (TTM)
69.9
Industry median 36.1 (152 companies)
Price to Book
1.9
PEG (TTM)
Data unavailable (needs 8 quarters of EPS).
Institutions holding %
6.42%
FII + DII, latest filed period
Piotroski Score
Data unavailable.
Relative return vs Nifty50, qtr %
23.0
Relative return vs Sector, qtr %
16.3
Free Cash Flow
₹-2 Cr
as of March 31, 2026
Industry median ₹-0 Cr (198 companies)
EPS Growth (YoY)
-25.00%
as of June 30, 2026
Industry median 26.14% (180 companies)
Net Profit Growth (TTM)
-19.77%
as of June 30, 2026
Industry median 6.21% (175 companies)
Operating Revenue Growth (TTM)
-11.40%
as of June 30, 2026
Industry median 9.08% (175 companies)
Profit Growth (YoY)
-35.88%
as of Sept. 30, 2025
Industry median 22.20% (176 companies)
Revenue Growth (YoY)
-56.34%
as of June 30, 2026
Industry median 14.05% (173 companies)
Current Ratio
1.81
as of March 31, 2026
Industry median 1.84 (197 companies)
Debt to Equity
0.33
as of March 31, 2026
Industry median 0.14 (186 companies)
Interest Coverage
1.75
as of June 30, 2026
Industry median 10.58 (182 companies)
Net Margin
1.22%
as of Sept. 30, 2025
Industry median 9.35% (179 companies)
Operating Margin (EBIT)
4.91%
as of June 30, 2026
Industry median 14.22% (181 companies)
Operating Margin (TTM)
2.37%
as of June 30, 2026
Industry median 12.41% (182 companies)
Return on Assets
1.54%
as of March 31, 2026
Industry median 5.54% (180 companies)
Return on Capital Employed
6.84%
as of March 31, 2026
Industry median 12.43% (181 companies)
Return on Equity
3.04%
as of March 31, 2026
Industry median 9.66% (179 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

2 of 6 met
  • No Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • Yes Debt to equity is below 0.5 (0.33)
  • No Return on equity is 15% or more (3.0%)
  • No Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

3 of 3 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.0% pledged)

Peer comparison

1 of 3 met
  • Yes 1-year return beats the industry median
  • No Revenue growth beats the industry median
  • No Profit growth beats the industry median

Value and momentum

2 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Overvalued (above its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
2.8%
Low 99.2200 · High 103.6900
1W return
0.1%
Low 97.2400 · High 103.6900
1M return
16.4%
Low 86.4100 · High 103.9900
52W return
22.4%
Low 50.3100 · High 103.9900
Lifetime High ₹102.7200 (Sept. 30, 2026)
Lifetime Low ₹22.6000 (March 28, 2023)

Full price history and technicals →

Technicals

Full technicals, indicators & Volume/Delivery →

EMA & SMA

Bullish6
Bearish0
5D
101.2
10D
100.7
20D
98.1
50D
92.0
100D
86.5
200D
78.3

Delivery and volume

Day avg. delivery
63.7%
Week avg. delivery
70.8%
Month avg. delivery
58.3%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

101.88
Pivot
First resistance104.53
Second resistance106.35
Third resistance109.00
First support100.06
Second support97.41
Third support95.59
Day RSI65.5
Day MFI50.1
Day MACD3.70
Day MACD signal4.15

Beta

1M0.85
3M0.03
1Y1.35
3Y0.99

Price change analysis

↑ 16.4%
Over 1 Month
LowHigh
86.41103.99
↑ 16.3%
Over 3 Months
LowHigh
73.41103.99
↑ 92.8%
Over 6 Months
LowHigh
52.28103.99
↑ 22.4%
Over 1 Year
LowHigh
50.31103.99
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 69.9 (own history: 24.5–61.3)
Overvalued (above its own historical PE range)

Financials

View full financials, peers & valuation multiples →
Revenue (June 30, 2026)
₹45 Cr
Net profit (June 30, 2026)
₹1 Cr
Basic EPS (June 30, 2026)
₹0.3600

Ranks #110 of 184 in Pharmaceuticals & Biotechnology by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter37.71%
  • FII/FPI4.80%
  • Public55.87%

Largest holders

NameCategoryShares %Shares
Bina Rajesh GhataliaPromoter14.1200%4003584
Mihir Rajesh GhataliaPromoter10.0000%2835888
Nimit ImpexPromoter7.0900%2010000
Nimit Rajesh GhataliaPromoter4.0600%1150000
Elysian Wealth FundPublic3.1200%885000

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 37.71% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 4.18% to 4.80% in Jun 2026 qtr

Historical mutual fund holding

All shareholding details →

Insider trading, SAST & pledges

All 6 insider trades, 1 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
14 Dec 2021 Mira Mihir Ghatalia Promoter Buy 0 ₹0
14 Dec 2021 Nimit Impex Pvt Ltd Promoter group Buy 0 ₹0
14 Dec 2021 Nimit Rajesh Ghatalia Director Buy 0 ₹0
14 Dec 2021 Suraj Tradelinks Pvt Ltd Promoter group Buy 0 ₹0
14 Dec 2021 Bina Rajesh Ghatalia Promoter Buy 0 ₹0
14 Dec 2021 Chetan Mehta Director Buy 0 ₹0

All insider and SAST disclosures →

Deals (Bulk & Block)

All 615 deals, with filters and CSV →
DateClientDealActionQuantityPriceExchange
30 Sep 2026 ARYA RAVI MANIRAM Bulk Buy 144,423 100.0100 NSE
30 Sep 2026 ARYA RAVI MANIRAM Bulk Buy 144,423 100.0100 NSE
28 Aug 2026 VAYUMIND INNOVATIONS PRIVATE LIMITED Bulk Buy 274,415 88.9700 NSE
26 Aug 2026 VAYUMIND INNOVATIONS PRIVATE LIMITED Bulk Buy 154,471 80.4500 NSE
26 Aug 2026 VAYUMIND INNOVATIONS PRIVATE LIMITED Bulk Buy 154,471 80.4500 NSE
4 Aug 2026 SHREE SALASAR PROPERTIES & FIN.(P)LTD. Bulk Buy 200,000 84.0000 NSE
17 Apr 2026 SHAH SANJAY JAYKANT Bulk Buy 150,000 81.5100 NSE
17 Feb 2026 INARAA FINANCIAL SERVICES PRIVATE LIMITED Bulk Sell 143,000 66.9500 NSE
12 Feb 2026 SHREE SALASAR PROPERTIES & FIN.(P)LTD. Bulk Buy 250,000 70.3300 NSE
12 Feb 2026 NISHITH ATULBHAI SHAH Bulk Sell 258,145 70.5400 NSE

All bulk and block deals →

Corporate Actions

Full history (4 events) →

Bonuses, splits, buybacks and other events. Dividends are listed separately above.

Ex-dateTypeSubject
23 Sep 2024OTHERAnnual General Meeting
29 Aug 2023OTHERAnnual General Meeting
22 Sep 2022OTHERAnnual General Meeting
2 Sep 2021OTHER Annual General Meeting

All corporate actions →

Board Meetings

View board meeting history →

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
14 Aug 2026 Financial Results Yes
30 May 2026 Financial Results Yes
29 May 2026 Financial Results Yes
11 Feb 2026 Financial Results Yes
13 Nov 2025 Financial Results Yes

Corporate Announcements

All 233 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
3 Oct 2026 Disclosure of material issue Aarey Drugs & Pharmaceuticals Limited has informed regarding Disclosure of material issue
3 Oct 2026 Disclosure of material issue Aarey Drugs & Pharmaceuticals Limited has informed regarding Disclosure of material issue
3 Oct 2026 Disclosure of material issue Aarey Drugs & Pharmaceuticals Limited has informed regarding Disclosure of material issue
30 Sep 2026 AGM/EGM Aarey Drugs & Pharmaceuticals Ltd - 524412 - Shareholder Meeting / Postal Ballot-Outcome of AGM
30 Sep 2026 Company Update Aarey Drugs & Pharmaceuticals Ltd - 524412 - Revised Outcome Of Board Meeting Dated 06-08-2026 Approved In Board Meeting 30-09-2026
30 Sep 2026 Others Aarey Drugs & Pharmaceuticals Ltd - 524412 - Board Meeting Outcome for OUTCOME OF BOARD MEETING HELD ON 30-09-2026
30 Sep 2026 Shareholders meeting Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 30, 2026
30 Sep 2026 Outcome of Board Meeting Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 06, 2026.
30 Sep 2026 Outcome of Board Meeting Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on September 30, 2026.
23 Sep 2026 Trading Window Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Healthy liquidity (Current Ratio 1.81)

Weaknesses

  • Low Return on Equity (3.0%)
  • Thin net profit margin (1.2%)
  • Declining revenue YoY (-56.3%)
  • Declining profit YoY (-35.9%)

Opportunities

Data unavailable.

Threats

  • PE above 35 (69.9) -- priced for continued strong execution
  • Weak interest coverage (1.7x) -- limited cushion against rising rates

Board of directors and corporate information →

F&O

View F&O, Options & Backtest →

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Aarey Drugs & Pharmaceuticals Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.